Cerilliant introduces new certified spiking solutions of corticosteroidspharmabiz.comSigma-Aldrich Corporation announced that the Cerilliant brand within its Applied Diagnostics and Testing Business Unit introduced four new Certified Spiking Solutions …
Patients with rare lung disease face agonizing treatment dilemmaMedical XpressBut a physician survey, an animal model and information about how the drug is metabolized suggest that a drug similar to sirolimus may be an option for LAM patients, accordin…
|
Cerilliant Introduces New Certified Snap-N-Spike® Solutions of Corticosteroids
Virtual Press Office (press release) LOUIS, April 16, 2014 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that the Cerilliant® brand within its Applied Diagnostics and Testing Business Unit introduced four new Certified Spiking Solutions® of the corticosteroids … |
|
Cerilliant Introduces New Certified Snap-N-Spike® Solutions of Corticosteroids
MarketWatch ST. LOUIS, April 16, 2014 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ:SIAL) today announced that the Cerilliant® brand within its Applied Diagnostics and Testing Business Unit introduced four new Certified Spiking Solutions® of the … |
Registry: DAPT Discontinuation Less Associated With Second-Gen DES …TCTMDFirst-generation DESs consisted of sirolimus-eluting (Cypher; Cordis, Johnson and Johnson) and paclitaxel-eluting devices (Taxus; Boston Scientific; Natick, MA). Second-generati…
|
National Cancer Institute investigating trial outliers to resurrect ‘failed’ drugs
FierceBiotech The patient, who had advanced bladder cancer, experienced a complete response for 14 months to the drug combination everolimus (Afinitor) and pazopanib (Votrient) in a Phase I trial. In the trial, investigators recruited 9 patients with advanced solid … |
IPO Report: Aldeyra Therapeutics (ALDX)Equities.comAcute anterior uveitis is often treated with corticosteroids (commonly used anti-inflammatory agents), but prolonged use of corticosteroids can lead to significant morbidity. In addition, SLS, discoid …
Angioplasty.Org |
Abbott’s Absorb Bioresorbable Scaffold Completes Enrollment in 3 Pivotal …
Angioplasty.Org The trials pit the Absorb Bioresorbable Vascular Scaffold against Abbott’s flagship everolimus-eluting XIENCE stent in almost 3,000 patients worldwide. The Absorb BVS also elutes everolimus. One of the primary theoretical advantages of this device is … Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United …Benzinga Abbott Completes Enrollment of Absorb(TM) Randomized Clinical Trials in the …Wall Street Journal |
|
Managing Asthma: The Pharmacist’s Role
Pharmacy Times According to the NAEPP, current guidelines recommend long-term treatment with inhaled corticosteroids because they are very effective in decreasing airway inflammation compared with any other single long-term control medication. 10-12 Using a … |
Doctor sues Queensland Government for almost $2 million over baby deliveryCourier MailDr Ismail, who later had two shoulder operations, had to have hydrocortisone injections and physiotherapy and will need further surgery. According to the claim, Dr Is…